4 results
To study pharmacokinetics of intravenously and intraperitoneally administered bevacizumab in patients with malignant ascites for whom there is no systemic anti-tumour treatment available.
Primary Objective:The primary objective of the study is to compare overall survival between the ASA404 plus docetaxel group and the placebo plus docetaxel group Key Secondary Objectives:To compare Progression-Free Survival (PFS) and the Overall…
To identify biological effects of bevacizumab therapy and to visualize distribution kinetics of 111In-bevacizumab with gamma-camera imaging.
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…